Drug intelligence / Profile preview

venetoclax + chidamide + azacitidine + decitabine + mitoxantrone + cytarabine + filgrastim

Development stage: Unknown
Lead developer: First Affiliated Hospital of Xiamen University
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

Venetoclax + Chidamide + Azacitidine + Decitabine + MAG (VCA followed by D-MAG) is a multi-agent sequential combination regimen being evaluated for the treatment of elderly, previously untreated acute myeloid leukemia (AML). The regimen is structured into two phases: an induction phase (VCA) consisting of venetoclax (a BCL-2 inhibitor), chidamide (a histone deacetylase inhibitor), and azacitidine (a hypomethylating agent), followed by a consolidation phase (D-MAG) consisting of decitabine (a hypomethylating agent) and the MAG regimen (mitoxantrone, cytarabine, and G-CSF). This combination is designed to exploit synergistic epigenetic modulation and apoptosis induction to improve complete remission rates and event-free survival in elderly AML patients who are ineligible for or intolerant of intensive chemotherapy.

Other names: veneclax + chidaniline + azacitidine + decitabine + MAGVenetoclax + Chidamide + Azacitidine + Decitabine + MAG

Targets

BCL-2 (BCL-2 family)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)DNMT (DNA methyltransferase)CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on venetoclax + chidamide + azacitidine + decitabine + mitoxantrone + cytarabine + filgrastim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on venetoclax + chidamide + azacitidine + decitabine + mitoxantrone + cytarabine + filgrastim.

Explore the full profile